Hua Jiang

374 Dianmian Avenue
Kunming, 650101, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Human Umbilical Cord Mesenchymal Stem Cells in Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) Therapy: Mechanisms, Clinical Efficacy, and Future Perspectives.

Human Umbilical Cord Mesenchymal Stem Cells in Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) Therapy: Mechanisms, Clinical Efficacy, and Future Perspectives.

Journal: Stem cell reviews and reports

Published: March 21, 2026

A Comprehensive Review of Radiomics in Pulmonary Nodule Management: Clinical Applications and Standardization Dilemmas.

A Comprehensive Review of Radiomics in Pulmonary Nodule Management: Clinical Applications and Standardization Dilemmas.

Journal: Current medical imaging

Published: December 22, 2025

Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma.

Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma.

Journal: Alimentary pharmacology & therapeutics

Published: December 10, 2025

Corrigendum: Characterization of the hepatic flora and metabolome in nonalcoholic fatty liver disease.

Corrigendum: Characterization of the hepatic flora and metabolome in nonalcoholic fatty liver disease.

Journal: Frontiers in microbiology

Published: April 01, 2025

Characterization of the hepatic flora and metabolome in nonalcoholic fatty liver disease.

Characterization of the hepatic flora and metabolome in nonalcoholic fatty liver disease.

Journal: Frontiers in microbiology

Published: November 15, 2024

Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.

Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.

Journal: EClinicalMedicine

Published: January 10, 2024

Identification of metabolic biomarkers associated with nonalcoholic fatty liver disease.

Identification of metabolic biomarkers associated with nonalcoholic fatty liver disease.

Journal: Lipids in health and disease

Published: May 30, 2023

Prediction of mortality and overt hepatic encephalopathy undergoing transjugular intrahepatic portosystemic shunt: a retrospective cohort study.

Prediction of mortality and overt hepatic encephalopathy undergoing transjugular intrahepatic portosystemic shunt: a retrospective cohort study.

Journal: Abdominal radiology (New York)

Published: May 10, 2023

Showing 1-8 of 8

Last Updated: 09/26/2026